Last Price
15.80
Today's Change
-0.15 (0.94%)
Day's Change
15.41 - 16.00
Trading Volume
49,741
Market Cap
659 Million
Shares Outstanding
41 Million
Avg Volume
36,945
Avg Price (50 Days)
12.89
Avg Price (200 Days)
12.14
PE Ratio
-9.75
EPS
-1.62
Earnings Announcement
08-Nov-2024
Previous Close
15.95
Open
15.58
Day's Range
15.41 - 16.0
Year Range
9.05 - 16.7
Trading Volume
49,741
1 Day Change
-0.94%
5 Day Change
9.72%
1 Month Change
28.35%
3 Month Change
35.86%
6 Month Change
31.45%
Ytd Change
42.99%
1 Year Change
65.62%
3 Year Change
62.72%
5 Year Change
62.89%
10 Year Change
62.89%
Max Change
62.89%
No result.
Sector: Healthcare - Healthcare
Industry: Biotechnology
Description:
Oculis Holding AG, a clinical-stage biopharmaceutical company, develops novel topical treatments for ophthalmic diseases for both back- and front-of-the-eye. The company's lead candidate is OCS-01, a topical dexamethasone formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for keratoconjunctivitis sicca, or dry eye disease; and OCS-05, a novel neuroprotective agent for acute optic neuritis and other neuro-ophtha disorders, such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The company is based in Zug, Switzerland.